Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Tokyo  >  ONO PHARMACEUTICAL CO., LTD.    4528   JP3197600004

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

ONO PHARMACEUTICAL : Fully Human Anti-PD-1 Antibody "ONO-4538/BMS-936558" Results from Phase 1 Study in Cancer Patients Published in New England Journal of Medicine (NEJM) and Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO) (94.2KB)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/04/2012 | 04:15am CEST

June 4th, 2012

ONO PHARMACEUTICAL CO., LTD. Corporate Communications Phone: +81-6-6263-5670 Fully Human Anti-PD-1 Antibody "ONO-4538/BMS-936558" Results from Phase 1 Study in Cancer Patients Published in New England Journal of Medicine (NEJM) and Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO)

Bristol-Myers Squibb Company (hereinafter referred to as "BMS") announced the results from Phase 1 study in patients with non-small-cell lung cancer (NSCLC), metastatic melanoma and renal cell carcinoma (RCC) to be published in New England Journal of Medicine (NEJM) and presented at 48th

Annual Meeting of the American Society of Clinical Oncology (ASCO), on June 2nd (US time).

ONO-4538/BMS-936558, a fully human anti-PD-1 antibody, is an investigational cancer immunotherapy generated under a research collaboration entered into in May 2005 between Ono Pharmaceutical Co., Ltd. (hereinafter referred to as "Ono") and Medarex, Inc. When Medarex, Inc. was acquired by BMS in

2009, it also granted BMS its rights to develop and commercialize the anti-PD-1 antibody in North America. Through the collaboration agreement entered into in September 2011 between Ono and BMS, Ono granted BMS exclusive rights to develop and commercialize ONO-4538/BMS-936558 in the rest of the world, except in Japan, Korea and Taiwan where Ono has retained all rights to develop and commercialize the compound.

BMS is conducting a Phase 2 study in RCC in North America and Europe, and plans to initiate registrational studies for anti-PD-1 this year in NSCLC and RCC, and late 2012, early 2013 for metastatic melanoma. On the other hand, Ono is conducting a Phase 2 study in metastatic melanoma in Japan, and plans to initiate clinical studies in RCC and NSCLC, taking account of the development status in United States and Europe.

Attached from the following page is the press release made by BMS for your information.

Investigational Anti-PD-1 Immunotherapy BMS-936558 Showed Clinical Activity in Phase 1

Trial of Patients with Previously-Treated Non-Small-Cell Lung Cancer, Metastatic Melanoma and Renal Cell Cancer

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ONO PHARMACEUTICAL CO., LT
07/14 ONO PHARMACEUTICAL : Notice Concerning Determination of Details of Issuance of S..
07/11 CELYAD : and ONO strike deal for NKR-2 in Japan, Korea and Taiwan
07/11 CELYAD : SA Enters Licensing Agreement with ONO Pharma for NKR-2 T-cell Immunot..
07/11 ONO PHARMACEUTICAL : enters into license agreement with Celyad for its allogenei..
07/06 ONO PHARMACEUTICAL : European Commission approves ONGENTYS® (opicapone) a novel ..
07/04 ONO RECEIVES MANUFACTURING AND MARKE : Carfilzomib; development code: ONO-7057),..
06/29 ONO PHARMACEUTICAL : Notice Concerning Issuance of Stock Options (Stock Acquisit..
06/28 ONO PHARMACEUTICAL : Opdivo® (nivolumab) Receives Breakthrough Therapy Designati..
06/15 ONO PHARMACEUTICAL : New Data on Opdivo (nivolumab) Indicate Benefit in Heavily ..
06/09 ONO PHARMACEUTICAL : First Presentation of Phase 2 CheckMate-142 Study Evaluatin..
More news
Sector news : Generic Pharmaceuticals
04:52pDJASTRAZENECA : 2Q 2016 -- Forecast
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJBAYER : 2Q 2016 -- Forecast
07/22DJMonsanto Wins EU Nod for New Biotech Soybeans
More sector news : Generic Pharmaceuticals
Advertisement
Financials ( JPY)
Sales 2017 297 336 M
EBIT 2017 -
Net income 2017 77 001 M
Finance 2017 129 348 M
Yield 2017 1,16%
P/E ratio 2017 27,77
P/E ratio 2018 17,83
EV / Sales 2017 7,44x
EV / Sales 2018 5,57x
Capitalization 2 341 041 M
More Financials
Chart ONO PHARMACEUTICAL CO., LT
Duration : Period :
ONO PHARMACEUTICAL CO., LT Technical Analysis Chart | 4528 | JP3197600004 | 4-Traders
Full-screen chart
Technical analysis trends ONO PHARMACEUTICA...
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 5 668  JPY
Spread / Average Target 43%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Gyo Sagara President & Representative Director
Kazuhito Kawabata Director, Managing Executive Officer & GM-Research
Hiroshi Awata Director, EVP & General Manager-Development
Isao Ono Director & Managing Executive Officer
Kei Sano Director & GM-Corporate Administration
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ONO PHARMACEUTICAL CO...-8.03%22 039
SUN PHARMACEUTICAL IND..-3.80%28 176
OTSUKA HOLDINGS CO LTD15.96%26 399
BIOMARIN PHARMACEUTICA..-10.67%15 190
ASPEN PHARMACARE HOLDI..23.55%11 984
TAISHO PHARMACEUTICAL ..32.55%9 538
More Results